$0.08
+14.12%Price chart
Aug 5Aug 19Sep 11Sep 21Oct 5Oct 19Oct 23Nov 2
Key dataNov 2, 2026
Open$0.08
From 52W high−66.06%
Volume1285.00
Market cap$2.97M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 2, 2026
Open
$0.08
From 52W high
−66.06%
Volume
1285.00
Market cap
$2.97M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
51.4
MomentumView details →
1D Return
+14.12%
YTD Return
+59.80%
SummaryUpdated Jun 1, 2026
Estrella Immunopharma, Inc. (NASDAQ:ESLA) is a preclinical-stage biopharmaceutical company founded to develop innovative T-cell therapies for treating blood cancers and solid tumors. Based in Emeryville, California, the company went public in September 2021 and focuses on developing engineered T-cell immunotherapies designed to harness the body's immune system to fight cancer. As a preclinical company, Estrella has not yet generated revenue and remains in the research and development phase of bringing its therapeutic candidates through clinical trials toward potential commercialization.
Similar companies
Latest newsMore news →
Estrella Immunopharma announced that Cheng Liu would leave his chief executive officer role and become chief scientific officer, effective October 25, 2026.6d agoEstrella Immunopharma appointed Cynthia Pussinen as chief executive officer, Class I director and chairperson of the board, effective October 25, 2026.6d ago